BioLineRx Ltd. (BLRX)
About BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $14.1M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $14.1M
- Shares outstanding
- 5.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 25, 2011
BioLineRx Ltd. (BLRX) Stock Price
- Trading 43% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BioLineRx Ltd..
Write a review
News about BioLineRx Ltd.
News & sentiment via Polygon.io
BioLineRx Ltd.: frequently asked questions
Is BioLineRx Ltd. an American company?
BioLineRx Ltd. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is BioLineRx Ltd. publicly traded?
Yes — BioLineRx Ltd. is a publicly traded company. Its stock trades under the ticker symbol BLRX on the NASDAQ.
What does BioLineRx Ltd. do?
BioLineRx Ltd. is an American Pharmaceuticals company in the Health & Beauty sector.
